How deadly is Prostate cancer?

['ⵙⵎⴷ ⵜⴰⴱⵔⴰⵜ ⴰⴷ']

ⵎⴰⵜⵜⴰ ⵜⴰⴽⵔⵉⴹⵜ ⵏ ⵓⴽⵏⵙⵉⵔ ⵏ ⴱⵔⵓⵙⵜⴰⵜ?

ⵉⴳⴰ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵓⴱⵔⵓⵜⴰⵙⵜ ⵓⵟⵟⵓⵏ ⵡⵉⵙⵙ ⵙⵉⵏ ⴳ ⵡⴰⵏⴰⵡⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⴳ ⵉⵔⴳⴰⵣⵏ ⴳ ⵓⵎⴰⴹⴰⵍ, ⵙ ⵡⴰⵜⵉⴳ ⵏ 1,276 ⵎⵍⵢⵓⵏ ⵏ ⵡⴰⴷⴷⴰⴷⵏ ⵉⵎⴰⵢⵏⵓⵜⵏ ⵉⵜⵜⵓⵣⵎⵎⴻⵎⵏ ⴳ ⵓⵙⴳⴳⵡⴰⵙ ⵏ 2018, ⵏⵏⴰ ⵉⵙⵎⴷⵢⴰⵏ 7,1% ⵙⴳ ⵡⴰⴷⴷⴰⴷⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⴳ ⵉⵔⴳⴰⵣⵏ.

ⴰⵙⵖⵍ ⵏ ⵜⵎⵜⵜⴰⵏⵜ ⵏ ⵍⴽⴰⵕⵙⵜⴰⵔ ⵏ ⴱⵕⵓⵚⵟⴰⵜ ⵉⴳⴰ ⴰⵡⴷ ⵢⴰⵜⵜⵓⵢⵏ, ⵙ ⵡⴰⵜⵉⴳ ⵏ ⵜⵎⵜⵜⴰⵏⵜ ⵏ 37,005 ⴳ ⵓⵎⴰⴹⴰⵍ ⴳ ⵓⵙⴳⴳⵡⴰⵙ ⵏ 2018.

ⵎⵇⵇⴰⵔ, ⴰⵙⵖⵍ ⵏ ⵜⵎⵜⵜⴰⵏⵜ ⵉⵎⵣⴰⵔⴰⵢⵏ ⴽⵉⴳⴰⵏ ⴳ ⵜⵙⴳⴰ, ⴷ ⵉⵣⵣⵍⵎⴹ ⵏ ⵉⴼⵔⵉⵇⵢⴰ ⵖⵓⵔⵙ ⴰⵙⵖⵍ ⵡⵉⵙⵙ ⵙⵎⵎⵓⵙ ⴳ ⵓⵎⴰⴹⴰⵍ ⴳ ⵜⵎⵜⵜⴰⵏⵜ ⵏ ⵍⴽⴰⵕⵙⵜⴰⵜ ⴳ ⵓⴱⵕⵓⵚⵟⴰⵜ, ⴷ ⵏⵉⵊⵉⵔⵢⴰ ⵖⵓⵔⵙ ⵉⵎⵣⴷⴰⵖⵏ ⴷ ⵜⴷⴰⵎⵙⴰ ⵜⴰⵎⵇⵇⵔⴰⵏⵜ ⴳ ⵜⵙⴳⴰ ⴰⴷ.

ⴳ ⵏⵉⵊⵉⵔⵢⴰ, ⵉⴳⴰ ⵓⴽⵏⵙⵉⵔ ⵏ ⵜⴰⴱⵔⵓⵜⴰⵙⵜ ⵓⴽⵏⵙⵉⵔ ⴰⴽⴽⵡ ⵉⴳⴳⵓⵜⵏ ⴷ ⵓⴽⵏⵙⵉⵔ ⴰⴽⴽⵡ ⵉⵛⵇⵇⴰⵏ ⵉ ⵉⵔⴳⴰⵣⵏ, ⵙ ⵡⴰⵜⵉⴳ ⵏ 32,8 ⵏ ⵡⴰⴷⴷⴰⴷⵏ ⴷ 16,3 ⵏ ⵜⵎⵜⵜⴰⵏⵜ ⴳ ⴽⵓⵍ 100.000 ⵏ ⵉⵔⴳⴰⵣⵏ.

ⵓⴳⴳⴰⵔ ⵏ ⵙⵏⴰⵜ ⵜⵉⴽⴽⴰⵍ ⵏ ⵓⵙⵖⵍ ⵏ ⵜⵎⵜⵜⴰⵏⵜ ⴳ ⴰⵎⵔⵉⴽⴰ ⵏ ⵓⴳⴰⴼⴰ.

ⴰⵙⵉⵙⵙⵏ ⵏ ⵡⴰⵟⵟⴰⵏ ⵙ ⵜⵉⵖⵣⵉ, ⵉⵙⵓⴳⴰⵎ ⵉⴷⵔⵓⵙⵏ ⵉ ⵓⵙⵉⵙⵙⵏ ⴷ ⵓⵙⵉⵙⵙⵏ, ⴷ ⵓⵙⵔⵔⵓⵙ ⵏ ⵉⵙⵎⵎⴰⵍⵏ ⴷ ⵓⵙⵎⵉⵙⵉ ⵏ ⵉⵎⴷⵢⴰⵡⵏ ⴷⴰ ⵉⵙⵔⵙⵏ ⴳ ⵓⵙⵖⵍ ⵏ ⵜⵎⵜⵜⴰⵏⵜ ⴳ ⵏⵉⵊⵉⵔⵢⴰ.

ⴳ ⵜⵎⵓⵔⴰ ⵉⵎⵓⵏⵏ, ⵉⴳⴰ ⵓⴽⵏⵙⵉⵔ ⵏ ⵓⴱⵔⵓⵙⵜⴰⵜ ⴰⵎⵏⵜⵉⵍ ⵡⵉⵙⵙ ⵙⵉⵏ ⴳ ⵜⵎⵜⵜⴰⵏⵜ ⵏ ⵍⴽⵏⵙⵉⵔ ⴳ ⵉⵔⴳⴰⵣⵏ, ⵙ ⵡⴰⵜⵜⴰⵢⵏ ⵏ 40,0000 ⵏ ⵓⵔⴳⴰⵣⵏ ⵉⵜⵎⵓⵜⵜⵉⵏ ⵙⴳ ⵜⵎⴰⴹⵓⵏⵜ ⴽⵓ ⴰⵙⴳⴳⵡⴰⵙ.

ⴰⵙⵖⵍ ⵏ ⵜⵎⵜⵜⴰⵏⵜ ⵏ ⵍⴽⴰⵕⵙⵜⴰⵏ ⵏ ⴱⵕⵓⵚⵟⴰⵜ ⵉⴳⴳⵡⵣ ⵙ ⵉⵎⵉⴽ ⵉⵎⵉⴽ ⵙⴳ ⵜⵣⵡⵓⵔⵉ ⵏ ⵉⵙⴳⴳⵡⴰⵙⵏ ⵏ 1990, ⵎⴰⵛⴰ ⵉⵙⵓⵍ ⵉⴳⴰ ⵢⴰⵏ ⵡⴰⴷⴷⴰⴷ ⵉⵅⴰⵜⴰⵔⵏ ⵏ ⵜⴷⵓⵙⵉ.

ⵙ ⵓⵎⴰⵜⴰ, ⵉⴳⴰ ⵓⴽⵏⵙⵉⵔ ⵏ ⴱⵔⵓⵙⵜⴰⵜⴰ ⵢⴰⵜ ⵜⵎⴰⴹⵓⵏⵜ ⵉⵔⵖⴰⵏ, ⵙⵍⴰⵡⴰⵏ ⴰⴽⴽⵡ ⴳ ⵜⵎⵏⴰⴹⵉⵏ ⴳ ⵓⵔ ⵉⵍⵍⵉ ⵓⴽⵛⵛⵓⵎ ⵉ ⵡⴰⵎⵎⴰⴽⵏ ⵏ ⵓⵖⴰⵎⵓⵙ ⴷ ⵓⵙⵜⴰⵍ.

ⵎⴰⵛⴰ, ⴰⵙⵉⵙⵙⵏ ⴷ ⵓⵙⵎⴽⵍ ⵏ ⵣⵉⴽ ⵉⵖⵢ ⴰⴷ ⵉⵙⵖⵓⴷⵓ ⵜⵉⵢⴰⴼⵓⵜⵉⵏ ⵙ ⵢⴰⵜ ⵜⵖⴰⵔⴰⵙⵜ ⵉⵅⴰⵜⴰⵔⵏ ⴷ ⴰⴷ ⵉⴽⴼⵍ ⵉⵙⵖⵍⵏ ⵏ ⵜⵎⵜⵜⴰⵏⵜ.

['ⵉⵙⵓⵎⴰⵔ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

['ⴰⵙⴱⴷⵉⴷ: ⴰⵎⵙⵏⵉⵊⵊⵉ']

['ⴰⵙⵉⵜ ⴰⴷ ⵉⵜⵜⵓⴼⴽⴰ ⵖⴰⵙ ⵉ ⵓⵡⵜⵜⴰⵙ ⵏ ⵓⵙⵙⵍⵎⴷ ⴷ ⵓⵙⵏⵖⵎⵙ, ⵓⵔ ⵉⴳⵉ ⴰⵙⴼⴽ ⵏ ⵓⵎⵛⴰⵡⴰⵕ ⵏ ⵓⴷⵓⵙⵜⵓⵔ ⵏⵖⴷ ⵜⵡⵓⵔⵉⵡⵉⵏ ⵜⵉⵣⵣⵓⵍⴰⵏⵉⵏ.']

['ⵓⵔ ⵉⵇⵇⵉⵏ ⴰⴷ ⵉⵜⵜⵓⵙⵎⵔⵙ ⵓⵎⵍⴰⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵓⵙⵎⵔⵙ ⵏ ⵓⵙⵎⵉⴳⵍ ⵏⵖⴷ ⵓⵙⵓⵊⵊⵉ ⵏ ⵜⵎⵓⴽⵔⵉⵙⵜ ⵏ ⵜⴷⵓⵙⵉ ⵏⵖⴷ ⵜⵎⴰⴹⵓⵏⵜ, ⴷ ⵡⵉⵏⵏⴰ ⵉⵔⴰⵏ ⴰⵙⵇⵇⵙⵉ ⴰⵎⵙⵏⵉⵊⵊⵉ ⴰⵡⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⵉⵇⵇⴰⵏ ⴰⴷ ⵙⴰⵡⵍⵏ ⴷ ⵓⵎⵙⵏⵉⵊⵊⵉ ⵉⵜⵜⵓⵥⵍⴰⵢⵏ.']

['ⵙ ⵡⴰⵍⵍⵍⵉ ⵉⵜⵜⵓⵢⴰⵏⵏⴰ, ⵜⴰⵔⴰⵜⵙⴰ ⵏ ⵓⵏⵢⵓⵔⴰⵍ ⵏⵏⴰ ⵉⵜⵜⴰⴽⴽⴰⵏ ⵜⵉⵎⵔⴰⵔⵓⵜⵉⵏ ⵉ ⵉⵙⵇⵙⵉⵜⵏ, ⵓⵔ ⴷⴰ ⵜⵜⵉⵍⵉ ⴰⴽⴽⵡ ⵜⵓⵙⴷⵉⴷⵜ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵓⵡⵏⵖ ⵏ ⵓⵟⵟⵓⵏ. ⵙ ⵓⵎⴷⵢⴰ, ⵓⵟⵟⵓⵏ ⵏ ⵎⴷⴷⵏ ⵉⵜⵜⵓⵙⵏⴼⴰⵍⵏ ⵖⴼ ⵜⵎⴰⴹⵓⵏⵜ ⵉⵥⵍⵉⵏ.']

['ⵚⵓⴰⵍ ⵙⵓⵍ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⵏⵏⴽ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⵙⵙⵉⵡⵍ ⵏ ⵜⴷⵓⵙⵉ ⵢⴰⴹⵏ ⵉⵇⴱⵍⵏ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ. ⵓⵔ ⴰⴽⴽⵡ ⴰⴷ ⵜⵙⵙⴼⵍⴷ ⴰⵙⵏⴰⵍ ⵏ ⵓⵊⵉⵊⵊⵉ ⴰⵣⵣⵓⵍⴰⵏ ⵏⵖⴷ ⴰⴷ ⵜⵣⴰⵢⴷ ⴳ ⵓⵙⵓⵜⴳ ⵏⵏⵙ ⴰⵛⴽⵓ ⵏⵜⵜⴰⵜ ⴰⵢⴷ ⵜⵙⵙⵖⵔⴷ ⴳ ⵓⵙⵉⵜ ⴰⴷ. ⵎⴽ ⵜⵓⵔⴷⴰ ⴰⴷ ⵖⵓⵔⴽ ⵉⵍⵍⴰ ⵡⴰⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ ⵉⵣⵣⴳⵔⵏ, ⵙⵎⴷ 911 ⵏⵖⴷ ⴰⴷ ⴷⵉⴷⵜ ⵜⴰⵍⵙ ⴷⴰⵔ ⵜⴰⴷⴰⵍⴰ ⵏ ⵓⵣⵣⵔⴰⵢ ⵏ ⵣⵉⴽⴽ. ⵓⵔ ⵜⵍⵍⴰ ⵜⵓⵇⵇⵏⴰ ⵏ ⵓⵊⵉⵊⵊⵉ ⴷ ⵓⵎⵏⵉⴳ ⵙ ⵓⵙⵉⵜ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ. ⵓⵔ ⴷⴰ ⵜⵙⴽⴰⵔ ⴱⵢⵓⵎⵉⴷⵍⵉⴱ ⵏⵖⴷ ⵉⵎⵙⵡⵓⵔⵉⵏ ⵏⵏⵙ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⴷⵔⴰⵡ ⴳ ⵓⵙⵉⵜ ⴰⴷ ⴽⵔⴰ ⵏ ⵓⵙⵎⴷⵢⴰ, ⵙ ⵡⴰⵡⴰⵍ ⵏⵖⴷ ⵙ ⵓⵙⵏⵓⵎⵍ, ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵍⵍⴰⵏ ⴳ ⵓⴷⵖⴰⵔ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ.']

['ⴰⵙⴱⴰⴷⵓ: ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⴼⵓⵙ']

['ⴰⵛⵔⵓⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ']

['ⵎⴽ ⵜⵛⵛⵉⵖⴰⵍⴷ ⵙ ⵜⵛⵛⵉⵢⵜ ⵎⴰⵙⴷ ⴽⵔⴰ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ ⵏⵏⴰ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵏⵖⴷ ⵜⵉⵙⵏⵙⵉ ⵏⵏⵓⵏ ⴷⴰ ⵉⴽⵛⵎⵏ ⴳ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵣⵔⴼ ⵏⵏⵓⵏ, ⵜⵣⵎⵔⴷ ⴰⴷ ⵜⴰⵍⵙⴷ (ⵏⵖ ⴰⵎⴷⵢⴰⵣ ⵏⵏⴽ) ⴰⴷ ⵜⵙⵏⵎⵍⴷ ⵉ ⵡⴰⵙⵉⵜ ⵏⵏⵓⵏ ⵙ ⵓⵙⵓⵜⵔ ⵏ ⵓⵙⵙⵉⴷⴼ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⵉⵙⵏⴼⴰⵔⵏ, ⵏⵖⴷ ⴰⴷ ⵜⴱⴷⴷⴷ ⵜⵉⵍⵉⵜ ⵏⵏⵙⵏ.']

['ⵉⵏⴰⵓⴰⵏ ⴰⵂⴰⵏ ⴰⴾⵜⴰⴱ ⵙ ⴰⵍⴾⵉⵜⵜⴰⴱ ⵙ ⵎⵢⵍ (ⵉⴾⵉⴰⴷ ⵙ ⴰⴾⵜⴰⴱ "ⵎⵢⵍ" ⵉ ⵎⵢⵍ)']

['DMCA ⵜⵙⵙⵓⵜⵔ ⴰⵙⵎⵉⵙⵉ ⵏⵏⴽ ⵏ ⵓⵎⴳⴰⵍ ⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵉⴽⵛⵎ ⴳ ⵓⵙⵎⵎⴰⵍ ⴰⴷ: (1) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵡⵓⵔⵉ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⵙⵏⵜⵍ ⵏ ⵓⵎⴳⴰⵍ; (2) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵓⵎⴰⵢⵜ ⵉⵃⴱⴰⵏ ⵉⵣⵔⴼⴰⵏ ⴷ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵅⵚⵚⴰⵏ ⴰⴼⴰⴷ ⴰⴷ ⵏⴰⴼ ⵜⵓⵎⴰⵢⵜ; (3) ⵉⵏⵖⵎⵉⵙⵏ ⵏ ⵓⵎⵢⴰⵡⴰⴹ ⴰⴽⴷⴽ, ⴳ ⵉⵍⵍⴰ ⵡⴰⵏⵙⴰ ⵏⵏⴽ, ⵓⵟⵟⵓⵏ ⵏ ⵜⵉⵍⵉⴼⵓⵏ ⴷ ⵡⴰⵏⵙⴰ ⵏ ⵓⵍⵉⴽⵜⵕⵓⵏ; (4) ⴰⵙⵉⵡⴹ ⵏⵏⴽ ⵎⴰⵙ ⴷⴰⵔⴽ ⵜⴰⵍⵍⵉⵍⵜ ⵉⵖⵓⴷⴰⵏ ⵏ ⵓⵙⵏⴽⴷ ⵎⴰⵙ ⵜⵓⵎⴰⵢⵜ ⵙ ⵜⵖⴰⵔⴰⵙⵜ ⵏⵏⴰ ⵜⵙⵙⵔⴳⴰⵍ ⵓⵔ ⵜⴽⴽⵉ ⵜⵓⵔⴰⴳⵜ ⵙⴳ ⵖⵓⵔ ⵡⴰⵏⵏⴰ ⵉⵟⵟⴰⴼⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ, ⵏⵖⴷ ⴰⵎⴷⵢⴰⵣ ⵏⵏⵙ, ⵏⵖⴷ ⵙ ⵓⵙⵡⵓⵔⵉ ⵏ ⴽⵔⴰ ⵏ ⵓⵙⵍⴳⵏ; ']

['(5) ⴰⵙⵉⵙⵙⵉⴾⵉ ⵏⵢⵜ, ⵉⴾⴼⴰⵏ ⵙ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⵜⵉⴷⵉⵜ, ⴰⵙ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵏⴰⵙⴰⵏ ⵓⵉⵏ ⵢⵎⵢⵍ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⴷ ⴰⵙ ⵉⵍⴰ ⴰⴾⴰⵉⴰⴷ ⵉ ⴰⵙⵓⵋ ⵏ ⴰⵍⵆⴰⴾⵓⵎ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜⵢⵏ ⵜⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉⵏ ⴰⴾⴰⵉⴰⴷ ⵓⵉ ⴰⵋⵋⴰⵏⵢⵏ']

['ⴷ (6) ⴰⴾⴰⵔⵓⵙ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵎⵢⵗ ⵓⴰ ⵉⵋⵋⴰⵏ ⵙ ⵢⵎⵢⵍ ⵏ ⵎⵓⵙⵏⴰⵜ ⵏ ⵉⴾⵉⵜⴱⴰⵏ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ']

['ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵙⴰⴾⵏⵢ ⵏ ⵉⵙⴰⵍⴰⵏ ⵓⵉⵏ ⴰⵋⵋⵓⵜⵏⵢⵏ ⴰⴷⴷⵓⴱⴰⵜ ⴰⴷ ⵢⵈⵈⵉⵍ ⴰⵙⵉⵓⴰⴷ ⵏ ⴰⴾⴰⵉⴰⴷ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏ ⴰⵍⵆⵉⴷⵎⴰⵜ ⵏⵢⵜ']

['ⴰⵎⵢⴰⵡⴰⴹ']

['ⵙⵓⴾⵢⵍ ⵉⵢⵎⴰⵍ ⵉⵢⵎⴰ ⵙ ⴽⴰⴾⴰⵎⴰⵍ ⴰⵙⵉⵙⵜⴰⵏ/ⴰⵙⵓⵋ']

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['ⴰⵜⵜⴰⵢⵏ']

['ⴷⴰ ⵉⵙⵙⵎⵔⴰⵙ ⴱⵢⵓ ⵎⵉⴷⵍⵍⵉⴱ ⵉⵎⴰⵙⵙⵏ ⵏ ⵓⵙⵉⴳⴳⵍ ⵉⵎⵉⴽⵙⵉⵍⵏ (ⴰⵍⴳⵓⵔⵉⵜⵎ ⵏ ⵓⵍⵎⵎⵓⴷ ⵏ ⵉⵎⵉⵙ) ⵉ ⵓⵙⵓⴼⵖ ⵏ ⵉⵎⵣⵉⵏⵏ ⵏ ⵉⵙⵇⵙⵉⵜⵏ ⴷ ⵜⵎⵔⴰⵔⵓⵜⵉⵏ.']

['ⴷⴰ ⵏⵙⵙⵏⵜⵉ ⵙ 35 ⵎⵍⵢⵓⵏ ⵏ ⵜⵥⵕⵉⴳⵉⵏ ⵏ ⵜⵙⵏⵉⵊⵊⵉⵜ ⵜⴰⴱⵢⵓⵎⵉⴷⵉⴽⵜ ⵏ ⴱⴰⴱⵎⵉⴷ/ⵎⵉⴷⵍⵉⵏ. ⵓⵍⴰ ⴰⵡⴷ ⵜⵉⴼⵔⴽⵉⵏ ⵏ ⵡⵉⴱ ⵏ ⵔⴰⴼⵉⵏⴷⵡⵉⴱ.']

['ⴰⵜ-ⵓ-ⴰⵗ "ⴰⵍⵓⴰⵈⴰⵏ" ⴰⴷ "ⴰⴾⴼⴰⵣ"']